424 related articles for article (PubMed ID: 34321239)
1. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
2. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
3. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
Tan J; Zheng X; Li M; Ye F; Song C; Xu C; Zhang X; Li W; Wang Y; Zeng S; Li H; Chen G; Huang X; Ma D; Liu D; Gao Q
Oncogene; 2021 Jun; 40(22):3845-3858. PubMed ID: 33966038
[TBL] [Abstract][Full Text] [Related]
4. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; ; deFazio A; McNeish IA; Bowtell DD; Swisher EM; Dobrovic A; Wakefield MJ; Scott CL
Nat Commun; 2018 Sep; 9(1):3970. PubMed ID: 30266954
[TBL] [Abstract][Full Text] [Related]
5. Secondary Somatic Mutations Restoring
Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O'Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL;
Cancer Discov; 2017 Sep; 7(9):984-998. PubMed ID: 28588062
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
7. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
[TBL] [Abstract][Full Text] [Related]
8. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a
Hurley RM; McGehee CD; Nesic K; Correia C; Weiskittel TM; Kelly RL; Venkatachalam A; Hou X; Pathoulas NM; Meng XW; Kondrashova O; Radke MR; Schneider PA; Flatten KS; Peterson KL; Becker MA; Wong EM; Southey MS; Dobrovic A; Lin KK; Harding TC; McNeish I; Ross CA; Wagner JM; Wakefield MJ; Scott CL; Haluska P; Wahner Hendrickson AE; Karnitz LM; Swisher EM; Li H; Weroha SJ; Kaufmann SH
NAR Cancer; 2021 Sep; 3(3):zcab028. PubMed ID: 34316715
[TBL] [Abstract][Full Text] [Related]
10. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
11. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
12. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
13. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
[TBL] [Abstract][Full Text] [Related]
14. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
15. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Sanij E; Hannan KM; Xuan J; Yan S; Ahern JE; Trigos AS; Brajanovski N; Son J; Chan KT; Kondrashova O; Lieschke E; Wakefield MJ; Frank D; Ellis S; Cullinane C; Kang J; Poortinga G; Nag P; Deans AJ; Khanna KK; Mileshkin L; McArthur GA; Soong J; Berns EMJJ; Hannan RD; Scott CL; Sheppard KE; Pearson RB
Nat Commun; 2020 May; 11(1):2641. PubMed ID: 32457376
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
[TBL] [Abstract][Full Text] [Related]
17. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher EM; Kwan TT; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Aghajanian C; Konecny GE; O'Malley DM; Leary A; Provencher D; Welch S; Chen LM; Wahner Hendrickson AE; Ma L; Ghatage P; Kristeleit RS; Dorigo O; Musafer A; Kaufmann SH; Elvin JA; Lin DI; Chambers SK; Dominy E; Vo LT; Goble S; Maloney L; Giordano H; Harding T; Dobrovic A; Scott CL; Lin KK; McNeish IA
Nat Commun; 2021 May; 12(1):2487. PubMed ID: 33941784
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract][Full Text] [Related]
20. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study.
Zouzoulas D; Tsolakidis D; Tzitzis P; Chatzistamatiou K; Theodoulidis V; Sofianou I; Grimbizis G; Timotheadou E
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
